PE20190512A1 - Conjugados de anticuerpo anti-egfr y farmaco - Google Patents

Conjugados de anticuerpo anti-egfr y farmaco

Info

Publication number
PE20190512A1
PE20190512A1 PE2018003191A PE2018003191A PE20190512A1 PE 20190512 A1 PE20190512 A1 PE 20190512A1 PE 2018003191 A PE2018003191 A PE 2018003191A PE 2018003191 A PE2018003191 A PE 2018003191A PE 20190512 A1 PE20190512 A1 PE 20190512A1
Authority
PE
Peru
Prior art keywords
halo
hydrogen
optionally substituted
antibody
drug
Prior art date
Application number
PE2018003191A
Other languages
English (en)
Inventor
Erwin R Boghaert
Andrew J Souers
Andrew C Phillips
Andrew S Judd
Milan Bruncko
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PE20190512A1 publication Critical patent/PE20190512A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a un conjugado de anticuerpo y farmaco (ADC) anti-receptor del factor de crecimiento epidermico humano (hEGFR), siendo el farmaco un inhibidor de Bcl-xL de formulas estructurales (IIa), (IIb), (IIc) y (IId), donde Ar1 es (a), (b), (c), entre otros, opcionalmente sustituidos por halo, hidroxi, nitro, entre otros; Ar2 es (aa), (bb), (cc), entre otros, opcionalmente sustituidos por halo, hidroxi, nitro, entre otros; Z1 se selecciona entre N, CH, entre otros; Z2a y Z2b son un enlace, O, S, S(O)2, entre otros; R' es (ab) o (ac); X' es -O- u otros; n es 0-3; G es un poliol, una sal, entre otros; SPa es oxigeno, -N(H)-, arileno, entre otros; m2 es 0-12; R1 y R2 son hidrogeno, metilo, halo, entre otros; R4 es hidrogeno, alquilo inferior, entre otros; R11a y R11b son hidrogeno, halo, metilo, metoxi, entre otros; R12 es R', hidrogeno, ciano, entre otros; R13 es heteroalquileno opcionalmente sustituido, heterocicleno opcionalmente sustituido, entre otros; #, si esta unido a R', se une en cualquier atomo sustituible de este, siendo el punto de union a un enlazador L segun la formula estructural (I), donde D es el farmaco inhibidor de Bcl-xL de formula IIa, IIb, IIc o IId; Ab es el anticuerpo anti-hEGFR; LK es la union covalente entre el enlazador (L) y el anticuerpo anti-hEGFR (Ab); y m es un numero entero entre 1 y 20. Tambien se refiere a composiciones y metodos de preparacion. La presente invencion es util para el tratamiento del cancer mediante inhibicion o reduccion de los tumores solidos
PE2018003191A 2016-06-08 2017-06-07 Conjugados de anticuerpo anti-egfr y farmaco PE20190512A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662347416P 2016-06-08 2016-06-08

Publications (1)

Publication Number Publication Date
PE20190512A1 true PE20190512A1 (es) 2019-04-10

Family

ID=59078219

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018003191A PE20190512A1 (es) 2016-06-08 2017-06-07 Conjugados de anticuerpo anti-egfr y farmaco

Country Status (21)

Country Link
US (2) US20190343961A1 (es)
EP (2) EP3468996B1 (es)
JP (3) JP2019521106A (es)
KR (2) KR20230035690A (es)
CN (4) CN109563168A (es)
AU (1) AU2017277517A1 (es)
BR (1) BR112018075636A2 (es)
CA (1) CA3027178A1 (es)
CL (2) CL2018003527A1 (es)
CO (1) CO2018013497A2 (es)
CR (1) CR20180614A (es)
DO (2) DOP2018000272A (es)
EC (1) ECSP19000157A (es)
IL (3) IL308054A (es)
MX (2) MX2018015286A (es)
PE (1) PE20190512A1 (es)
PH (1) PH12018502602A1 (es)
RU (1) RU2018147224A (es)
SG (2) SG11201810970WA (es)
TW (2) TW202320860A (es)
WO (1) WO2017214282A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562190A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
CN116284404A (zh) 2016-06-08 2023-06-23 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
WO2018218004A1 (en) * 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
US11717575B2 (en) 2019-05-20 2023-08-08 Mabplex International Co., Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
PE20220218A1 (es) 2019-05-20 2022-02-02 Novartis Ag Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso
KR20210097627A (ko) 2020-01-30 2021-08-09 성균관대학교산학협력단 면역관문 억제제 및 엑소좀 분비 억제제를 포함하는 항체-약물 접합체 및 이를 포함하는 약학적 조성물
IL298284A (en) 2020-05-19 2023-01-01 Servier Lab Para-amino-benzyl linkers, a process for their preparation and their use in conjugates
IL303048A (en) 2020-11-24 2023-07-01 Novartis Ag BCL-XL inhibitor antibody-drug conjugates and methods of using them
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022271722A1 (en) * 2021-06-22 2022-12-29 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof
CN117580846A (zh) * 2022-04-29 2024-02-20 石药集团中奇制药技术（石家庄）有限公司 具有肝靶向递送效应的化合物及其寡聚核苷酸缀合物
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法
WO2023223097A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody drug conjugates

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1726514A (en) 1926-11-01 1929-08-27 Firm Ferd Liebschner & Sohn Picker for looms
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
DK2270149T3 (en) 1999-04-09 2016-05-09 Kyowa Hakko Kirin Co Ltd PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE.
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
DK1522590T3 (da) 2000-06-28 2009-12-21 Glycofi Inc Fremgangsmåde til fremstilling af modificerede glykoproteiner
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
DK2357006T3 (en) 2002-07-31 2015-12-21 Seattle Genetics Inc Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CN1950496B (zh) 2004-04-15 2015-02-04 格利科菲公司 在低等真核生物中产生半乳糖基化糖蛋白
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
CN101415679A (zh) 2006-02-02 2009-04-22 辛塔佳有限公司 水溶性cc-1065类似物及其缀合物
JP5557746B2 (ja) 2007-11-28 2014-07-23 メルサナ セラピューティックス，インク． 生体適合性生分解性フマギリンアナログ複合体
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス， インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US8889675B2 (en) * 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
SG11201402686UA (en) 2011-12-05 2014-06-27 Igenica Inc Antibody-drug conjugates and related compounds, compositions, and methods
EP2794582A1 (en) 2011-12-23 2014-10-29 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
KR102557309B1 (ko) 2012-05-15 2023-07-20 씨젠 인크. 자가-안정화 링커 접합체
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
EP3126006A1 (en) * 2014-03-21 2017-02-08 AbbVie Inc. Anti-egfr antibodies and antibody drug conjugates
CN113209306A (zh) * 2014-12-09 2021-08-06 艾伯维公司 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物
US20160158377A1 (en) * 2014-12-09 2016-06-09 Abbvie Inc. BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same
SG10201911585XA (en) 2014-12-09 2020-01-30 Abbvie Inc Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same

Also Published As

Publication number Publication date
AU2017277517A1 (en) 2019-01-03
JP2023166395A (ja) 2023-11-21
CO2018013497A2 (es) 2019-02-08
JP2019521106A (ja) 2019-07-25
KR20230035690A (ko) 2023-03-14
IL308054A (en) 2023-12-01
CN109563168A (zh) 2019-04-02
BR112018075636A2 (pt) 2019-04-09
JP2022058351A (ja) 2022-04-12
TW201806626A (zh) 2018-03-01
CN116059394A (zh) 2023-05-05
EP4104865A1 (en) 2022-12-21
US20230077680A1 (en) 2023-03-16
ECSP19000157A (es) 2019-01-31
RU2018147224A (ru) 2020-07-14
CL2019002270A1 (es) 2019-11-15
CA3027178A1 (en) 2017-12-14
CL2018003527A1 (es) 2019-03-15
RU2018147224A3 (es) 2020-10-14
EP3468996B1 (en) 2022-05-04
IL263571A (en) 2019-01-31
WO2017214282A1 (en) 2017-12-14
MX2018015286A (es) 2019-08-12
CR20180614A (es) 2019-07-29
KR20190015526A (ko) 2019-02-13
CN116059201A (zh) 2023-05-05
CN116059202A (zh) 2023-05-05
SG11201810970WA (en) 2019-01-30
SG10201914060WA (en) 2020-03-30
IL291073A (en) 2022-05-01
PH12018502602A1 (en) 2019-09-30
MX2022007807A (es) 2022-07-19
DOP2022000182A (es) 2022-09-30
DOP2018000272A (es) 2019-01-31
EP3468996A1 (en) 2019-04-17
US20190343961A1 (en) 2019-11-14
TW202320860A (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
PE20190512A1 (es) Conjugados de anticuerpo anti-egfr y farmaco
CY1124071T1 (el) Συζευγμα αντισωματος anti-her3 φapmakoy
PE20181347A1 (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
CY1121573T1 (el) Συζευγμα αντισωματος anti-her2-φαρμακου
CY1123660T1 (el) Ενωσεις 1-τετραϋδροπυρανυλοκαρβονυλο-2,3-διυδρο-1η-ινδολιου για την αγωγη του καρκινου
AR120080A1 (es) Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
IN2014CN04961A (es)
MX2022003740A (es) Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
AR092538A1 (es) Inhibidores de girasa triciclica
CY1116945T1 (el) Παραγωγα ινδολιζινης, διεργασια για την παρασκευη αυτης και θεραπευτικη χρηση αυτης
CY1117157T1 (el) Υποκατεστημενο παραγωγο ισοκινολινης
MX347240B (es) Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos.
AR095019A1 (es) Derivados de amatoxina
BR112014027190A2 (pt) pirrolobenzodiazepinas
JP2016508130A5 (es)
RU2014140739A (ru) Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
AR077292A1 (es) Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
MX2019009428A (es) Conjugados de pirrolobenzodiazepinas y anticuerpos.
MX2016016515A (es) Derivados de auristatina y conjugados de los mismos.
NZ599777A (en) Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
JP2014528466A5 (es)
ECSP11011189A (es) Moduladores de los receptores tipo toll
AR077849A2 (es) Compuestos y composiciones como inhibidores de proteina quinasa
AR066348A1 (es) Inhibidores de las iap